A Phase 2 Randomised, Double-Blind, Parallel Group, 4-Week Treatment, Adaptive Dose Finding, Multi-Centre Study Evaluating the Efficacy, Safety, Tolerability and Pharmacokinetics of up to Three Different Oral Doses of AZD1386 and Placebo in Patients With Osteoarthritis of the Knee
Phase 2
- Conditions
- Pain
- Registration Number
- JPRN-jRCT2080220732
- Lead Sponsor
- AstraZeneca
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Patients with OA of the knee
Exclusion Criteria
- A current diagnosis of another form of arthritis, in addition to OA
- History, and/or presence of somatic disease, which may interfere with the objectives
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method